GLP-1 Receptor Agonist: A Literature Course

A GLP-1 receptor agonist is a molecule that binds to and activates the glucagon-like peptide-1 receptor (GLP-1R), the cell-surface receptor for the gut incretin hormone GLP-1. Reviews of the class have described these agents as incretin-based compounds developed first for glycaemic and weight-related endpoints, with a second wave of research examining cardiovascular, renal, hepatic, neurological and inflammatory endpoints (PMID 38201269).

This course is organised into six modules. Each summarises only what the cited papers examined and reported, and each closes with a short statement of the limits of that evidence. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health condition, medication or laboratory result. Nothing here describes a protocol, and no outcome described below should be read as an expected result.

Module 1 — What It Is and How It Has Been Studied

Definition and class

The term describes a pharmacological class rather than a single substance. Members are peptides or peptide-like molecules that act as agonists at GLP-1R. Some are single-receptor agonists; others are engineered to engage more than one incretin receptor. Researchers characterised tirzepatide, for example, as a dual agonist at both the GIP receptor and GLP-1R, and described it as imbalanced and biased because its activity was not equivalent at the two receptors (PMID 32730231).

Origin

The class originates from work on the incretin system — the observation that gut-derived hormones influence insulin secretion after nutrient intake. Reviews covering effects beyond obesity and diabetes traced the development of GLP-1R-directed agents from that endocrine physiology into agents studied across multiple organ systems (PMID 38201269). Within the literature reviewed here, named compounds include semaglutide, studied in a diabetic mouse model (PMID 41344533), and tirzepatide and dulaglutide, both examined in a clinical analysis of beta-cell function in type 2 diabetes (PMID 33236115).

Forms and settings studied

• In vitro receptor pharmacology — binding, signalling and receptor trafficking assays used to profile agonist behaviour (PMID 32730231).
• Animal disease models — rodent models of diabetic kidney injury (PMID 39630101) and high-fat-diet/streptozotocin diabetic mice with cardiac microvascular endpoints (PMID 41344533).
• Human trial analyses — analyses of fasting indices of beta-cell function and insulin sensitivity in adults with type 2 diabetes (PMID 33236115).
• Observational and narrative work — a cohort analysis of treatment discontinuation (PMID 38787563) and narrative reviews of dietary intake (PMID 39175746).

Limits of the evidence in Module 1

The papers verified for this course do not constitute a complete map of the class. They do not include head-to-head comparisons of every marketed agent, and the animal and in vitro work describes specific molecules under specific conditions rather than the class as a whole. Statements that begin "GLP-1 receptor agonists do…" are class generalisations that individual studies were not designed to test.

Module 2 — Mechanism as Described in the Literature

At the receptor level, the most detailed mechanistic description in this set came from work profiling tirzepatide, where researchers reported that the molecule engaged the GIP receptor and GLP-1R unequally and displayed biased signalling at GLP-1R — favouring some intracellular pathways over others rather than reproducing the signalling fingerprint of native GLP-1 (PMID 32730231). That paper illustrates a general point in the field: agonists at the same receptor need not produce the same downstream signal.

Downstream of receptor activation, the clinical analysis in type 2 diabetes examined fasting markers of insulin secretion and insulin sensitivity, and researchers reported improvements in indices of beta-cell function and insulin sensitivity in the treated groups (PMID 33236115). A review of combination therapy described GLP-1 receptor agonists and SGLT2 inhibitors as acting through distinct and potentially complementary mechanisms, with the authors discussing why the two classes were investigated together (PMID 28432726).

Organ-level mechanistic hypotheses have also been tested in animals. In a model of diabetic kidney injury, the study reported that GLP-1 receptor agonist treatment reduced markers of ferroptosis — an iron-dependent form of cell death — through a β-Klotho-mediated pathway (PMID 39630101). In diabetic mice, researchers reported that semaglutide attenuated cardiac microvascular injury in the HFD/STZ model (PMID 41344533). Behavioural and nutritional mechanisms sit alongside these: a narrative review of dietary intake in people taking GLP-1 and dual GIP/GLP-1 receptor agonists reported changes in food intake and flagged unanswered questions about diet composition and nutrient adequacy (PMID 39175746).

Limits of the evidence in Module 2

Mechanism established in a cell line or a mouse does not demonstrate the same mechanism in humans. The β-Klotho/ferroptosis pathway and the cardiac microvascular findings were reported in rodent and cellular systems and were not tested as clinical endpoints in those papers. Biased agonism data describe receptor behaviour in assays, not patient outcomes.

Module 3 — Reported Outcomes by Study

The table summarises the model, endpoint and reported direction of findings for each verified paper. It is a description of what was measured, not a statement of expected benefit.

Limits of the evidence in Module 3

The set mixes evidence tiers: an in vitro assay, two animal studies, one post hoc clinical analysis, one observational cohort and several reviews. Surrogate endpoints such as fasting insulin-secretion indices are not the same as long-term clinical outcomes, and reviews inherit the limitations of the studies they summarise. None of the reported findings constitute a promise of benefit for any individual.

Module 4 — GLP-1 Receptor Agonist Side Effects: What Studies Report

Gastrointestinal complaints dominate the published adverse-event picture for this class. A clinical review on dietary management reported nausea, vomiting, constipation, diarrhoea and related upper-gut symptoms among patients treated with GLP-1 receptor agonists, and framed dietary strategies as a response to those symptoms (PMID 39722834). A separate narrative review of dietary intake reported reduced food intake and raised concerns about protein and micronutrient adequacy and diet quality as areas needing research (PMID 39175746).

Dermatological reports have also appeared. A systematic review collected published cases and studies of hair loss associated with GLP-1 receptor agonist use, and the authors reported that the available evidence was limited, heterogeneous and insufficient to establish causation (PMID 41111833).

Tolerability also appears indirectly through persistence data: in a cohort of patients with obesity and/or type 2 diabetes, researchers reported that many discontinued GLP-1 receptor agonist therapy during the study period, a pattern the authors linked in part to tolerability and access factors (PMID 38787563). Reproductive safety has been addressed in reviews rather than trials: a clinical review of pregnancy described the human safety evidence as evolving and emerging, with limited data available (PMID 39993530), and a gynaecology review discussed contraception, fertility and perioperative considerations as open questions in routine care (PMID 40183300).

Limits of the evidence in Module 4

Case reports and systematic reviews of case-level data cannot establish that a compound caused an event. Frequency figures from trials reflect the populations, doses and durations studied. Rare events, long-term effects and interactions with other medicines are poorly captured by the papers in this set, and none of them was designed as a dedicated long-term safety study.

Module 5 — Pharmacokinetics Where Data Exist

The verified literature for this course contains receptor pharmacology rather than dedicated human pharmacokinetic studies. The closest mechanistic data come from assays in which researchers compared how a dual agonist engaged GIP and GLP-1 receptors and reported differences in potency and signalling relative to the native hormones (PMID 32730231). Pharmacodynamic exposure can be inferred only indirectly from trial design: the clinical analysis in type 2 diabetes examined once-weekly tirzepatide across a dose range of 1 mg to 15 mg with dulaglutide 1.5 mg and placebo as comparators over the trial period (PMID 33236115), which reflects the weekly administration interval used in that study.

Where the literature in this set touched on absorption-adjacent issues, it did so through gastrointestinal physiology: reviews reported delayed gastric emptying and upper-gut symptoms as features relevant to nutrition and symptom management (PMID 39722834), and reviews of gynaecological care discussed consequences for co-administered oral medicines as a topic requiring attention (PMID 40183300).

Limits of the evidence in Module 5

No half-life, bioavailability, clearance or volume-of-distribution values are reported in the papers verified here, so none are stated. Dose ranges appearing in a trial protocol describe what that trial administered to its enrolled population under medical supervision; they are not transferable information and are not comparable across molecules.

Module 6 — Regulatory Status

Several GLP-1 receptor agonists are approved prescription medicines in the United States, the European Union and other jurisdictions for type 2 diabetes and, for some products, for chronic weight management. Approved products carry agency-reviewed labelling that specifies indication, population, administration and warnings. Reviews in this set discussed clinical use within that regulatory framework, including combination use with other glucose-lowering drug classes (PMID 28432726) and off-label questions raised in gynaecological practice (PMID 40183300).

Separately, peptide materials sold as "research use only" (RUO) are not approved drug products. RUO labelling indicates laboratory research supply and explicitly excludes human or veterinary use; such material is not assessed by regulators for identity, purity, sterility or safety in people. Compounded preparations occupy a third category: in the United States, compounding of copies of commercially available approved drugs is restricted, and the scope for compounding semaglutide- or tirzepatide-type products has shifted with FDA drug shortage listings and subsequent enforcement positions. Individual state boards of pharmacy and medicine add further rules. Nothing in this module is legal advice; regulatory status changes over time and varies by country and state.

Limits of the evidence in Module 6

Published research papers describe experiments, not legality. A compound appearing in a peer-reviewed study carries no implication of approval, and approval in one jurisdiction or for one indication does not extend to others. Regulatory summaries here are general and may be outdated by the time they are read.

What the Studies Did Not Test

Across the verified literature, several gaps are explicit. The in vitro pharmacology did not test clinical outcomes (PMID 32730231). The kidney and cardiac studies were conducted in animal and cell systems and did not test human renal or cardiac events (PMID 39630101, PMID 41344533). The clinical analysis examined fasting surrogate indices rather than long-term complications (PMID 33236115). The dietary reviews identified nutrient adequacy, protein intake and diet quality as open research needs rather than resolved questions (PMID 39175746), and the pregnancy review described the evidence base as still emerging (PMID 39993530).

None of these papers studied healthy individuals using non-prescription or research-grade material outside medical care, none evaluated unapproved combinations assembled by consumers, and none reported on product quality from non-pharmaceutical sources. Reviews of effects beyond obesity and diabetes called for additional controlled research before broader conclusions could be drawn (PMID 38201269). This page summarises literature for educational purposes only; it is not medical advice, and questions about any medication or symptom belong with a licensed physician.

References

• Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight, 2020)
• GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes (Cells, 2023)
• GLP-1 Receptor Agonists Alleviate Diabetic Kidney Injury via β-Klotho-Mediated Ferroptosis Inhibition (Advanced Science, 2025)
• Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor (Diabetes, Obesity & Metabolism, 2017)
• The use of GLP-1 receptor agonist medications for benign gynecology (Current Opinion in Obstetrics & Gynecology, 2025)
• Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs (Obesity Pillars, 2024)
• Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (Journal of Clinical Endocrinology & Metabolism, 2021)
• Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review (Cureus, 2025)
• GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence (Clinical Medicine, 2025)
• GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes (JAMA Network Open, 2024)
• A GLP-1 receptor agonist semaglutide attenuates cardiac microvascular injury in HFD/STZ-induced diabetic mice (European Journal of Pharmacology, 2026)
• Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist (Diabetes, Metabolic Syndrome and Obesity, 2024)